Evidence map›Paper›PMID 29058699›Full record

ArticleBone marrow transplantation2018

Transbronchial biopsy in the management of pulmonary complications of hematopoietic stem cell transplantation.

D N O'Dwyer, A S Duvall, M Xia, T C Hoffman, K S Bloye, C A Bulte, X Zhou, S Murray, B B Moore, G A Yanik

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. The Diagnostic Approach to Pulmonary Complications in Allogeneic Hematopoietic Cell Transplantation: To Biopsy or Not?Transplant infectious disease : an official journal of the Transplantation Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

D N O'DwyerDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
A S DuvallDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
M XiaDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
T C HoffmanDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
K S BloyeDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
C A BulteDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
X ZhouDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
S MurrayDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
B B MooreDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
G A YanikDepartment of Pediatrics, University of Michigan, Ann Arbor, MI, USA.
University of Michigan–Ann Arbor · US

Funding

miR-29b and autophagy regulate alveolar macrophage function post-BMTR01AI117229 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOORE, BETHANY B. · 2015 to 2019
$2.2M
HSCT-induced alterations in DCs to promote IL-17 and lung pathologyR01HL127805 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MOORE, BETHANY B. · 2016 to 2018
$1.5M
NHLBI NIH HHS R01 HL127805NIAID NIH HHS R01 AI117229
6 · The paper itself

Abstract

The utility of transbronchial biopsy in the management of pulmonary complications following hematopoietic stem cell transplantation (HSCT) has shown variable results. Herein, we examine the largest case series of patients undergoing transbronchial biopsy following HSCT. We performed a retrospective analysis of 130 transbronchial biopsy cases performed in patients with pulmonary complications post HSCT. Logistic regression models were applied to examine diagnostic yield, odds of therapy change and complications. The most common histologic finding on transbronchial biopsy was a nonspecific interstitial pneumonitis (n=24 cases, 18%). Pathogens identified by transbronchial biopsy were rare, occurring in <5% of cases. A positive transbronchial biopsy significantly increased the odds of a subsequent change in corticosteroid therapy (odds ratio (OR)=3.12; 95% confidence interval (CI) 1.18-8.23; P=0.02) but was not associated with a change in antibiotic therapy (OR=1.01; 95% CI 0.40-2.54; P=0.98) or changes in overall therapy (OR=1.92; 95% CI 0.79-4.70; P=0.15). Patients who underwent a transbronchial biopsy had increased odds of complications related to the bronchoscopy (OR=3.33, 95% CI 1.63-6.79; P=0.001). In conclusion, transbronchial biopsy may contribute to the diagnostic management of noninfectious lung injury post HSCT, whereas its utility in the management of infectious pulmonary complications of HSCT remains low.

Indexed as

BronchoscopyFemaleHematopoietic Stem Cell TransplantationHumansLungMaleMiddle AgedTransplantation Conditioning

Identifiers

PMID29058699
PMCPMC5803310
OpenAlexW2765269273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.